Samsung Biologics News and Resources

Samsung Biologics has received an A- rating for water security from the Carbon Disclosures Project (CDP), achieving ‘Leadership’ status in its first year of participation. The recognition highlights the company’s commitment to efficient water resource management as part of its

Samsung Biologics has announced an expanded collaboration with LigaChem Biosciences to provide antibody-drug conjugate (ADC) services. This partnership, which builds on their previous work in ADC programs for solid tumors, will involve Samsung Biologics supporting LigaChem’s ADC pipeline at a

Samsung Biologics, a contract development and manufacturing services provider (CDMO), has been recognised for the fourth consecutive year in the prestigious Dow Jones Sustainability World Index (DJSI). This accolade highlights the company’s ongoing commitment to integrating sustainable business practices throughout

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has signed a series of manufacturing agreements with a European pharmaceutical company, valued at more than USD 668 million. The contracts will run until December 2031, contributing to the company’s

Samsung Biologics has been awarded the ISO 37301:2021 certification for Compliance Management Systems, recognising the company’s commitment to organisational governance and adherence to global regulatory standards. This new certification, presented by the British Standards Institution (BSI), underlines Samsung Biologics’ ongoing

Samsung Biologics, a global contract development and manufacturing organization (CDMO), has secured a $1.24 billion contract manufacturing agreement with an unnamed Asia-based pharmaceutical company. The deal, which runs until December 2037, is the largest contract ever signed by a single

Samsung Biologics has launched a new high-concentration formulation platform, S-HiCon, designed to support the development of high-dose biopharmaceuticals. The platform is aimed at improving formulation stability, reducing viscosity, and ensuring the efficacy of drugs with high concentration requirements. The platform

Samsung Biologics, a global contract development and manufacturing organisation (CDMO), announced its membership in the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner. This marks the first time a Korean CDMO has joined the PSCI, a group dedicated to

Samsung Biologics, a Korean contract development and manufacturing organisation (CDMO), has announced a substantial manufacturing agreement with a large, unnamed U.S. drugmaker. The deal, valued at 1.46 trillion Korean won (approximately $1.05 billion), was disclosed on Tuesday and signifies a